Teleukin is under clinical development by Philogen and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Teleukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Teleukin (F16-IL2) was under development for the treatment of relapse acute myeloid leukemia (AML) and non-small cell lung cancer. The drug candidate is administered as an intravenous infusion. It is an immunocytokine of the human monoclonal antibody fragment F16 (scFv) against the extra-domain A1 of tenascin-C fused, via a short 5-amino acid linker, to a recombinant form of the human cytokine interleukin-2 (IL-2). It is developed based on immunocytokine technology. It was also under development for the treatment of solid tumors including bladder cancer, breast cancer, metastatic melanoma, mesothelioma, non-small cell lung cancer (NSCLC), prostate cancer, sarcoma (second line) and metastatic Merkel cell carcinoma (first line). It is under development for non-small cell lung cancer.
Philogen is a biotechnology company that develops biopharmaceuticals for the treatment of angiogenesis-related disorders. The company’s product portfolio include NidlegyTM, Fibromun, Darleukin, Dodekin, Dekavil and ABBV-022. The company provides dekavil and tetravil and others targeted at the treatment of severe pathologies such as cancer, rheumatoid arthritis and age-related macular degeneration. It offers DNA-encoded chemical libraries, antibody drug conjugates, immunocytokines, and antibody libraries, discovery of vascular targets, vascular targeting and easy iodine technology. The company is also advancing clinical development programs for the treatment of cancer and of chronic diseases. Philogen is headquartered in Siena, Italy.
For a complete picture of Teleukin’s drug-specific PTSR and LoA scores, buy the report here.